Bisoce

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisoce

What is Bisoce? Defining its Identity and Purpose

Property Description
Active ingredient Bisoprolol Fumarate
Form Oral film-coated tablet
Pharmacological class Cardioselective Beta-1 Adrenergic Blocking Agent
General purpose Cardiovascular support and blood pressure regulation
Origin Synthetic organic compound

Bisoce: Definition and Pharmacological Class

Bisoce is a pharmaceutical preparation containing the active component Bisoprolol Fumarate, which is classified as a cardioselective beta1-adrenergic blocking agent (or beta-blocker). It belongs to the class of cardiovascular medications designed for systemic regulation of heart and circulatory function. The core substance is a synthetic organic compound of established importance in global healthcare. This classification signifies its identity as a prescription-only (Rx) medication that exhibits a targeted, preferential effect on the beta1 receptors found primarily in the heart, as clinically recognized for its role in stabilizing heart activity.


Composition, Form, and General Purpose

Bisoce is a single-entity medication supplied for systemic action in the form of an oral film-coated tablet. It incorporates Bisoprolol Fumarate alongside solid pharmaceutical excipients necessary for stability and structure. The formulation allows for simple administration by mouth, which is standard for a medication intended to provide long-term, predictable regulation. The fundamental general purpose of Bisoce is to support the circulatory system by mediating the heart's response to natural internal stimuli. This medication is typically used to provide support in scenarios involving the management of elevated blood pressure and chronic cardiac strain.


How Cardioselectivity Defines Bisoce’s Action

The mechanism of Bisoce is centered on its highly selective antagonism of the beta1-receptors. This action is characterized by a predictable inhibitory effect on cardiac rate and contractility. In practical terms, this action translates into a clinical effect that gently diminishes the force and speed of the heart's contractions. Essentially, the drug works by mitigating the impact of sympathetic stimulation, which consequently reduces the heart's workload and its demand for oxygen. This defining feature forms the basis of the drug’s beneficial action within the cardiovascular system, contributing to more stable circulatory function.

Regulatory References

  1. WHO Model List of Essential Medicines (EML)
  2. WHO Essential Medicines List

What side effects are possible with Bisoce?

Possible Side Effects and Safety Information

The safety profile of Bisoce (Bisoprolol Fumarate) is organized and communicated through a regulatory framework that classifies potential adverse reactions by frequency and affected body system, strictly according to official government documentation.

Frequency-Classified Adverse Reactions

The official labeling outlines the documented incidence of potential effects. Very Common (ge 1/10) reactions include bradycardia (slow heart rate), specifically in patients treated for heart failure. Reactions classified as Common (ge 1/100 to < 1/10) often involve general symptoms like fatigue and dizziness, as well as gastrointestinal complaints (e.g., nausea, diarrhoea). Other documented effects, such as bronchospasm or sleep disorders, are categorized as Uncommon, while Hepatitis and hallucinations are considered Rare.


Serious Safety Considerations and Contextual Patterns

The label identifies several serious adverse reactions that warrant specific notice, including the potential for severe sinus bradycardia or the development of second or third-degree AV block. A worsening of pre-existing heart failure is also explicitly documented. Some reactions, such as dizziness and headache, are noted as transient and most likely at the beginning of treatment, typically resolving within the first one to two weeks of therapy.


Population-Specific Safety Notes

Safety constraints documented in regulatory sources apply to specific patient groups. Safety and effectiveness have not been established in pediatric patients. For diabetic patients, the medication may mask some symptoms of acute hypoglycemia, such as a rapid heart rate. Furthermore, the label requires additional caution when adjusting the dose in individuals with renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the Bisoce (Bisoprolol) overdose profile based on documented clinical manifestations, severe outcomes, and mandated emergency actions. All information in this section is based on authoritative government regulatory sources.


Documented Manifestations and Severe Outcomes

Overdosage is primarily associated with cardiovascular and systemic effects. Documented manifestations include bradycardia (abnormally slow heart rate), severe hypotension (low blood pressure), and potentially bronchospasm (difficulty breathing). Serious, life-threatening outcomes can include profound cardiac shock, severe hypoglycemia (low blood sugar), coma, and convulsions.


Emergency Actions and Required Monitoring

Regulatory instructions require users to seek medical help right away and contact a Poison Control Center immediately if an overdose is suspected or confirmed. Medical management involves supportive measures and specific agents like glucagon or atropine to counteract the cardiac effects. Continuous monitoring of vital signs and blood glucose levels is required for effective management and observation due to the risk of delayed symptoms.


Population-Specific Considerations

Regulatory documents highlight that hypoglycemia is a common and critical concern following this type of overdose in children. Newborns exposed to the drug prenatally must be monitored for the first three days of life for signs of bradycardia and low blood sugar.

Therapeutic Uses of Bisoce

What Bisoce Treats: Main Uses and Benefits

Bisoce is used for supportive management across key therapeutic domains, addressing symptoms related to heightened physiological activity and strain on the cardiovascular system. Its application is relevant in contexts involving heightened systemic burden.

This medication is commonly used to help manage essential hypertension, and may be part of symptomatic management for chronic, compensated heart failure and chronic stable angina pectoris. Its application is relevant across domains where additional symptomatic support is needed, addressing symptom clusters that may intensify temporarily or create noticeable physiological strain.

“This supportive use is relevant for easing symptoms that create noticeable physiological strain, which may help patients cope more steadily with symptom fluctuations.”

Bisoce provides support that helps ease the overall symptom burden associated with these chronic conditions. This supports general well-being during symptomatic phases and assists with maintaining functional stability.


Quick Fact: Relief for Cardiovascular Strain Bisoce supports the heart by helping to moderate rapid heart activity and systemic imbalance, a benefit often applied in scenarios requiring additional management of discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Bisoce?

The eligibility for Bisoce (Bisoprolol Fumarate) is strictly defined by regulatory authorities and focuses on the patient’s cardiac status and age. Adults are the established population for use in hypertension, chronic stable angina, and stable chronic heart failure.

Absolute Contraindications

Bisoce is contraindicated and must not be used by patients with specific severe conditions, including cardiogenic shock, overt cardiac failure, second or third degree atrioventricular (AV) block (without a pacemaker), and marked sinus bradycardia.

Age and Condition Restrictions

Use is not recommended in children and adolescents (under 18 years) because safety and efficacy are not established in the pediatric population. Patients with severe renal impairment or severe hepatic impairment are subject to a maximum daily dose of 10 mg for hypertension or angina. Use during pregnancy and breastfeeding is generally not recommended due to potential risks, and is only permitted if the clear clinical need outweighs the documented risks.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Bisoce

Category Details
Medicinal product categories with documented interactions Monoamine oxidase inhibitors (excluding MAO-B inhibitors); Class I Antiarrhythmic Agents; Calcium Channel Blockers (phenylalkylamine and benzothiazepine types); Digitalis Glycosides; NSAIDs; CYP3A4 Inhibitors and Inducers.
Specific interacting medicines (if explicitly listed) Verapamil, Diltiazem, Quinidine, Flecainide, Propafenone, Rifampin, Oral Aluminum Hydroxide, Grapefruit.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic Reinforcement (additive effects on cardiac function); Metabolic Interaction (inhibition or induction of CYP3A4 pathway); Reduced Absorption (gastrointestinal binding).

Interaction-Related Restrictions and Constraints

Classification Details
Interaction severity classification (as defined in official documents) Contraindicated/Strictly Avoided (e.g., MAOIs, certain Verapamil/Diltiazem co-administrations); Requires Timing Separation (e.g., Oral Aluminum Hydroxide).
Timing-based interaction rules Co-administration with Oral Aluminum Hydroxide antacids requires a separation of 2 hours to mitigate the labeled reduction in Bisoce's absorption.
Population-specific interaction notes In patients with severe renal impairment or severe hepatic impairment, the maximal labeled daily dose must not be exceeded due to documented reduced clearance, which increases the potential for accumulation and interaction-related effects.

Official Interaction Statements

The regulatory profile mandates strict limitations on certain combinations. The use of Bisoce with Calcium Channel Blockers (Verapamil, Diltiazem) and Class I Antiarrhythmics (e.g., Flecainide) is associated with severe pharmacodynamic reinforcement risk, potentially causing profound bradycardia and AV block. Metabolism via CYP3A4 is a documented pathway for exposure alteration; strong inhibitors may increase Bisoce's plasma concentration, while inducers like Rifampin may reduce it. This structure defines necessary co-administration controls based on official pharmacokinetic and pharmacodynamic data.

Mechanism of Action

Selective beta1-Receptor Blockade and Cardiac Stabilization

Bisoce's primary action is as a competitive antagonist at the beta1-adrenergic receptors found in the heart muscle. By preventing natural stress hormones (catecholamines) from binding, Bisoce suppresses the receptor-mediated signaling cascade, which includes reduced cAMP and calcium influx. This molecular interference directly translates into defined physiological adjustments, namely a negative chronotropic effect (slower heart rate) and a negative inotropic effect (reduced force of contraction), which decreases the heart’s workload and oxygen demand.

Modulating Systemic Pressure via Renal Pathway Inhibition

Bisoce engages mechanisms that regulate systemic fluid and vessel tone by acting on beta1 receptors in the kidneys' juxtaglomerular apparatus (JGA). This peripheral blockade suppresses the release of renin, the crucial initial step in activating the Renin-Angiotensin System (RAS). By interfering upstream in this humoral pathway, Bisoce attenuates the RAS-driven mechanisms that increase vascular resistance and fluid retention, contributing to the regulation of the circulatory system.

Mechanism Limitations: Selectivity and Rebound

The drug's cardioselectivity is dose-dependent and can be overcome at higher doses, leading to potential beta2 receptor blockade in other systems. Furthermore, its continuous antagonistic action can lead to receptor upregulation; hence, sudden cessation of the mechanism can result in a period of hyper-responsiveness to circulating catecholamines.

Dosage and Administration Information

Bisoce (Bisoprolol Fumarate) is administered orally as a film-coated tablet once daily (qDay), establishing a consistent daily intake routine. The tablet should be taken in the morning and must be swallowed whole with liquid. Intake may occur independently of food, as absorption is not significantly affected by meals.

Standard Labeled Dosing Regimens

The dosage pattern is based on the condition being treated and follows specific limits:

  • Hypertension/Angina: The typical starting dose is 5 mg once daily. The dose can be adjusted, but the maximum daily dose is 20 mg.
  • Chronic Heart Failure: This use requires a titration schedule beginning with a very low starting dose of 1.25 mg once daily. The dose is then increased gradually in a slow, step-wise pattern over several weeks, up to a maximum recommended dose of 10 mg daily.

Population-Specific Adjustments

Dose modifications apply to certain populations. For patients with severe hepatic or renal dysfunction (creatinine clearance < 40 mL/min), the initial daily dose is reduced to 2.5 mg, and the total daily dose should not exceed 10 mg. The use of Bisoce is generally not recommended for pediatric patients due to a lack of sufficient clinical experience.

Procedural Use Constraints

A critical constraint governing the use of Bisoce is the requirement for gradual dose reduction upon planned cessation of therapy. The treatment must not be stopped abruptly; instead, the dose must be slowly tapered over approximately one to two weeks.

Recent Clinical Evidence

Research Evidence / Overview of studies for Bisoce

This overview describes the official research and clinical trials that have been conducted on Bisoprolol Fumarate (Bisoce), focusing on the types of studies performed, what they monitored, and what remains to be fully characterized, according to scientific literature. This is a descriptive summary of the research landscape and is not clinical guidance.


Evidence for use in Essential Hypertension (Elevated Blood Pressure)

The research into Bisoce for managing elevated blood pressure primarily includes randomized, double-blind, placebo-controlled trials (RCTs), which are the most common type of study used to evaluate research outcomes.

In these studies, researchers monitored the change in participants' Systolic and Diastolic Blood Pressure (BP) measurements over defined time intervals. Studies comparing the treatment group to the placebo group recorded measurements of both systolic and diastolic blood pressure that were then compared over the observation periods. However, the follow-up durations were limited in many of the initial efficacy trials, typically focusing on short-term periods of three to twelve weeks.


Evidence for use in Chronic, Compensated Heart Failure

Research for Bisoce's use in chronic heart failure includes large-scale, multi-center trials. These studies focused on patients with stable heart failure, meaning their heart's pumping ability (ejection fraction) was reduced.

The studies monitored major, long-term, patient-relevant outcomes. Researchers examined outcomes related to all-cause mortality (survival) and the incidence of hospitalization due to sudden worsening of heart failure. Data from these trials reported measurements related to the all-cause mortality rate and the frequency of hospitalization events, which were then compared against the placebo group.


Research Gaps and What Remains Uncertain

The comprehensive research landscape, while establishing certain patterns, also highlights areas where research is ongoing or where data remain insufficient. The most extensive evidence from controlled trials is for conditions that are chronic and stable (e.g., compensated heart failure). Limited information is available for its use in patients who are acutely unstable or experiencing a severe, immediate decline in their condition.

Regarding more vulnerable groups, the safety and effectiveness was not established in the pediatric population (children). Findings describe group patterns, not personal outcomes. The research provides context but does not determine whether an individual will respond similarly to the patterns observed in the studies.

Key Studies & References

  1. CIBIS Investigators and Committees. A randomized trial of $beta$-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS).
  2. NICE Guideline NG136: Chronic heart failure in adults: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Bisoce (FAQ)


Q: What is the main reason Bisoce is prescribed?

Bisoce is officially indicated for the management of three cardiovascular conditions. The primary reasons it is prescribed are for treating elevated blood pressure (hypertension), chronic stable angina (chest pain), and stable chronic heart failure.


Q: Is Bisoce the same as Bisoprolol?

Bisoce is the brand name used for the active pharmaceutical ingredient. That ingredient is Bisoprolol Fumarate.


Q: How is Bisoce different from other similar medications?

Bisoce is classified as a cardioselective beta1-adrenergic blocking agent. This pharmacological identity means it has a preferential inhibitory effect on the beta1 receptors, which are found primarily in the heart muscle.


Q: Does Bisoce start working immediately, or does it take time?

Official pharmacokinetic data describes the absorption of Bisoce in the body. The maximum concentration of the medicine in the blood is typically reached within 2 to 4 hours after taking the tablet.


Q: How long do I need to take Bisoce?

Bisoce is officially indicated for the long-term management of chronic conditions such as stable chronic heart failure and elevated blood pressure. Information regarding the duration of treatment is typically decided based on the patient's condition.


Q: Can Bisoce be taken with herbal supplements?

The regulatory profile of Bisoce details potential interactions with products that affect the CYP3A4 metabolic pathway. The official label advises that patients inform their healthcare provider of all co-administered substances, including supplements, due to the potential for concentration changes.


Q: Does Bisoce affect the ability to exercise or engage in physical activity?

The mechanism of Bisoce involves reducing heart rate (negative chronotropic effect) and force of contraction. Fatigue and bradycardia (slow heart rate) are documented adverse reactions that may be experienced while taking the medicine.


Q: Is Bisoce used for conditions other than its main indication?

Regulatory documents list Bisoce's established indications as elevated blood pressure (hypertension), chronic stable angina, and stable chronic heart failure.


Q: Why is Bisoce prescribed as part of a combination therapy?

Bisoce is often used in combination strategies because it affects multiple cardiovascular mechanisms. It targets beta1 receptors in the heart to reduce workload while also suppressing the release of renin in the kidney to help modulate systemic pressure.


Q: Does Bisoce cause weight gain, and if so, how common is it?

Weight gain is a documented adverse reaction in the official safety profile. It is typically listed as an uncommon adverse reaction, meaning it is reported to occur in less than 1 in 100 people.


Q: Do older adults require special consideration before using Bisoce?

While official guidelines do not establish separate dosing requirements based solely on advanced age, special consideration is given to patients with existing health conditions. Dose reduction is specified for patients with severe hepatic or renal dysfunction, which may be relevant for older adults.


Q: Can Bisoce be prescribed for anxiety or performance-related stress?

Bisoce is officially indicated for the treatment of elevated blood pressure (hypertension), chronic stable angina, and stable chronic heart failure. Official regulatory documents specify the established indications and do not address other uses.


Q: Does Bisoce interact with alcohol?

Official regulatory information indicates that alcohol may potentiate the effects of Bisoce. This can potentially lead to increased blood pressure-lowering effects or an increased risk of dizziness.


Q: Can Bisoce cause sexual side effects, and how often does this happen?

Sexual disorders, such as impotence, are included in the official safety documentation. These effects are listed as an uncommon adverse reaction, meaning they are reported to occur in less than 1 in 100 people.


Q: How quickly can the full effects of Bisoce be expected?

Clinical trials for conditions like hypertension typically focused on short-term periods to evaluate the maximum therapeutic effect. Follow-up durations in these studies were often conducted over three to twelve weeks.


Q: What are the official safety classifications for Bisoce (e.g., in terms of risk)?

The regulatory profile includes a classification of potential risks for use during pregnancy. Its use is generally not recommended unless the clear clinical need outweighs the documented risk to the fetus.


Q: Does Bisoce affect cholesterol or triglyceride levels?

Disturbances in lipid metabolism are sometimes documented in the official adverse reaction listing. These effects, such as elevated triglyceride or cholesterol levels, are categorized in the safety profile.


Q: What are the general expectations for a patient starting treatment with Bisoce?

Patients may experience fatigue, dizziness, or headache, especially during the initial phase of treatment. These effects are noted in official documents as being transient, typically resolving within the first one to two weeks.


Q: Why is it important to tell my doctor about all vitamins when starting Bisoce?

The interaction profile of Bisoce includes the risk of potential reduction in absorption from the gastrointestinal tract and metabolic interference via the CYP3A4 pathway. For this reason, official labeling advises that patients provide a full list of co-administered substances, including vitamins and supplements.


Q: Is there a link between Bisoce and depression?

Depression is included in the official safety profile documentation. It is listed as an uncommon adverse reaction, reported to occur in less than 1 in 100 people.


Q: Are there any known interactions between Bisoce and common cold remedies?

Official documents note a risk of interaction with certain products found in cold remedies. These include sympathomimetic agents (decongestants) and non-steroidal anti-inflammatory drugs (NSAIDs), which may alter the therapeutic effect of Bisoce.


Q: Do users often misunderstand the 'failure' part in the condition Bisoce treats?

Bisoce is indicated for stable chronic heart failure. This term describes a long-term condition where the heart's pumping ability (ejection fraction) is reduced, rather than a sudden, complete stoppage of heart function.


Q: Does Bisoce interact with common over-the-counter pain relievers?

Official regulatory documents note a potential interaction between Bisoce and a category of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). Studies indicate that NSAIDs may reduce the blood pressure-lowering effect of Bisoce.


Q: Is it necessary to avoid certain foods or drinks while taking Bisoce?

According to official product information, Bisoce can generally be taken independent of meals. However, the regulatory documents specifically list grapefruit as a product that may interact with the medicine.


Q: Is Bisoce considered safe for long-term use?

Bisoce is indicated for the long-term management of chronic conditions such as stable heart failure and high blood pressure. Research evidence has examined its use in large-scale, multi-center trials for chronic, compensated heart failure, monitoring long-term outcomes such as all-cause mortality and hospitalization.


Q: Are the side effects of Bisoce permanent?

Regulatory information notes that certain common effects are transient, meaning they are short-lived. For example, symptoms like headache and dizziness are most likely to occur at the very beginning of treatment and generally resolve within the first one to two weeks.


Q: Can people with respiratory issues like asthma use Bisoce?

Official labeling includes specific warnings regarding Bisoce's use in patients with bronchospasm, which is common in conditions like asthma. Regulatory sources state that Bisoce is generally contraindicated in severe forms of these respiratory conditions.


Q: Does Bisoce affect blood sugar levels for people who have diabetes?

For patients who have diabetes, the regulatory profile notes a specific caution regarding Bisoce's use. It states that the medicine may mask certain signs of acute hypoglycemia (low blood sugar), particularly a rapid heart rate.


Q: Are there different types of Bisoce (e.g., tablet, extended-release)?

Bisoce is supplied as an oral film-coated tablet in different strengths. The standard administration pattern is once daily, which is consistent with a formulation designed for long-acting effect.


Q: Is there a generic version of Bisoce available?

Bisoce is the brand name for the active ingredient, which is Bisoprolol Fumarate. The active ingredient itself is the chemical entity and is available under this generic name.


Q: Does Bisoce interact with common anti-depressant medications?

Official documents list Monoamine Oxidase Inhibitors (MAOIs), a type of antidepressant, as a product category with documented interactions. Furthermore, certain other medicines that affect the CYP3A4 metabolic pathway may also alter Bisoce's concentration.


Q: What is the recommended approach for starting Bisoce treatment?

The approach for starting Bisoce treatment is dependent on the condition being addressed. For chronic heart failure, official guidelines describe a low starting dose followed by a slow, gradual increase, known as titration, over several weeks.


Q: Can Bisoce interact with high blood pressure medicines I already take?

Yes, the regulatory profile notes specific interactions with other blood pressure medicines. Co-administration with certain Calcium Channel Blockers, such as Verapamil and Diltiazem, is explicitly associated with a risk of reinforcing effects on cardiac function.


Q: What does the research say about Bisoce's ability to help prevent heart complications?

Large-scale clinical trials have examined the effect of Bisoce on major long-term outcomes for chronic heart failure. These studies monitored data related to the all-cause mortality rate and the frequency of hospitalization events due to sudden worsening of heart failure.

How should Bisoce be stored and disposed of?

How to Store and Dispose of Bisoce?


Bisoce (Bisoprolol Fumarate) must be stored strictly according to official regulatory labeling to ensure product quality and safety. The primary instruction is to keep the medicine out of the sight and reach of children.

Storage Requirements

Condition Regulatory Rule
Temperature Store below 30°C or below 25°C, depending on the specific packaging approved by regulatory authorities.
Protection Keep the tablets in their original packaging to protect from moisture and light. If supplied in a bottle, the container must be kept tightly closed.
Stability Do not use the tablets after the expiry date. Some bottle presentations have a limited shelf life after opening (e.g., 6 months or 100 days).

Disposal Instructions

Expired or unused Bisoce must be disposed of in accordance with local requirements. It is prohibited to throw away the medicine via wastewater or household waste. Consult a pharmacist for proper pharmaceutical waste disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisoce found in:

A-Z Index: